Publications by authors named "R Arbel"

Evidence regarding the high-dose (HD) vaccine's relative vaccine effectiveness (rVE) and absolute benefit in reducing influenza-related hospitalizations compared to the standard-dose (SD) vaccine is warranted. We estimated the adjusted rVE and the number needed to vaccinate (NNV) of the HD vaccine compared to the SD vaccine among Clalit Health Services members aged ≥65 years. Among 418,603 and 393,125 members vaccinated in the 2022-2023 and 2023-2024 influenza seasons, the adjusted rVE was 27% (95% CI: -12% to 61%) for 2022-2023 and 7% (95% CI: -36% to 42%) for 2023-2024, with NNV to prevent one hospitalization event being 2262 (95% CI: 1004 to ∞) and 7662 (95% CI: 1293 to ∞), respectively.

View Article and Find Full Text PDF

Parental support for adolescent emotion regulation is critical for adolescents' health. Yet, little is known about parents' daily support of adolescents' emotion regulation. This study aimed to typify daily co-parent supportive extrinsic emotion regulation (EER) profiles directed toward adolescents' daily distress and anger.

View Article and Find Full Text PDF

Goal pursuit is rife with obstacles triggering negative emotions. To persist in goal pursuit, individuals need to regulate these emotions using adaptive emotion regulation strategies. Reappraisal and emotional integration are two such strategies.

View Article and Find Full Text PDF

Patient satisfaction is an imperative factor in integrating telehealth services as a treatment modality in health care systems. Here, we compared patient satisfaction from telehealth versus in-person health care visits in a large heterogeneous population. We conducted a retrospective cohort study of patients making telehealth or in-person primary care visits between January 2021 and August 2022.

View Article and Find Full Text PDF
Article Synopsis
  • A study aimed to assess the effectiveness and safety of molnupiravir for COVID-19 treatment specifically within the FDA-defined intended-use population (IUP) in Israel.
  • The research involved 49,515 patients, matching 3,957 molnupiravir-treated individuals with 19,785 untreated individuals, focusing on hospitalization and mortality rates.
  • Results showed that molnupiravir significantly reduced rates of COVID-19-related hospitalizations and all-cause mortality compared to those not treated with the drug.
View Article and Find Full Text PDF